Apr 30, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 2: Future Directions in the Use of Oral SERDs for HR-Positive, HER2-Negative BC — Erica Mayer, MD, MPH, FASCO

CME information and select...

Apr 30, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive,...

Apr 30, 2026

Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics:

• Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00)
• Second-Line Treatment for Metastatic Breast Cancer (16:01)
• First-Line Therapy for Metastatic Disease (33:19)
• Adjuvant Therapy (35:26)
• Toxicity,...

Apr 27, 2026

Featuring perspectives from Dr Suresh S Ramalingam and Dr Helena Yu, including the following topics:

• Introduction: Genomics of EGFR (and HER2) (0:00)
• Metastatic Disease (9:30)
• Localized Disease (30:22)
• EGFR Exon 20 Insertion Mutations (46:57)
• New Agents (54:20)

CME information and select...

Apr 27, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR-Mutant NSCLC (eg, Nonmetastatic Disease, Exon 20 Insertion Mutations, Novel Agents) — Suresh S Ramalingam, MD